Etiologies of Melanoma Development and Prevention Measures: A Review of the Current Evidence
- PMID: 34638397
- PMCID: PMC8508267
- DOI: 10.3390/cancers13194914
Etiologies of Melanoma Development and Prevention Measures: A Review of the Current Evidence
Abstract
(1) Melanoma is the most aggressive dermatologic malignancy, with an estimated 106,110 new cases to be diagnosed in 2021. The annual incidence rates continue to climb, which underscores the critical importance of improving the methods to prevent this disease. The interventions to assist with melanoma prevention vary and typically include measures such as UV avoidance and the use of protective clothing, sunscreen, and other chemopreventive agents. However, the evidence is mixed surrounding the use of these and other interventions. This review discusses the heritable etiologies underlying melanoma development before delving into the data surrounding the preventive methods highlighted above. (2) A comprehensive literature review was performed to identify the clinical trials, observational studies, and meta-analyses pertinent to melanoma prevention and incidence. Online resources were queried to identify epidemiologic and clinical trial information. (3) Evidence exists to support population-wide screening programs, the proper use of sunscreen, and community-targeted measures in the prevention of melanoma. Clinical evidence for the majority of the proposed preventive chemotherapeutics is presently minimal but continues to evolve. (4) Further study of these chemotherapeutics, as well as improvement of techniques in artificial intelligence and imaging techniques for melanoma screening, is warranted for continued improvement of melanoma prevention.
Keywords: UV; artificial intelligence; melanoma; prevention; screening; sun safety; sunscreen; tanning.
Conflict of interest statement
A.R.D., C.S., B.T.F., S.W.W., M.A.T., B.D.K. and J.M.G. have no disclosures to report. L.J.G. discloses research support/PI from Helsinn Group, J&J, Mallinckrodt, Kyowa Kirin, Soligenix, Innate, miRagen, Galderma, Merck, BMS, and Stratpharma; the speakers’ bureau for Helsinn Group and J&J; and the scientific advisory board for Helsinn Group, J&J, Mallinckrodt, Kyowa Kirin, Regeneron, and Sanofi. Y.M.S. discloses research funding from Amgen, Regeneron, Roche, Tempest Therapeutics, and IP in a small biomarker startup named Wasaba.
References
-
- Cancer Stat Facts: Melanoma of the Skin. 2021. [(accessed on 30 June 2021)]; Available online: https://seer.cancer.gov/statfacts/html/melan.html.
-
- Jerant A.F., Johnson J.T., Sheridan C.D., Caffrey T.J. Early detection and treatment of skin cancer. Am. Fam. Physician. 2000;62:352–381. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
